Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RGLS4326 Administered Via SC Injection to Patients With Autosomal Dominant Polycystic Kidney Disease

NCT04536688 is registered in ClinicalTrials.gov with Regulus Therapeutics Inc. as lead sponsor.

NCT NCT04536688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04536688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RGLS4326 Administered Via SC Injection to Patients With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
Regulus Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2020
Completion date
November 12, 2021
Enrollment
19 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

polycystic kidney disease, autosomal dominant